Business Wire

AMP Raises $91 Million in Series D Funding to Revolutionize Waste

5.12.2024 15:00:00 CET | Business Wire | Press release

Share

Latest investment to support expansion to process municipal solid waste and single-stream recycling at scale

AMP Robotics Corp. (“AMP”), a leading provider of AI-powered sortation at scale for the waste and recycling industry, has raised $91 million in corporate equity in a Series D financing led by Congruent Ventures. The round featured participation from current and new investors, including Sequoia Capital, XN, Blue Earth Capital, Liberty Mutual Investments, California State Teachers Retirement System (CalSTRS), Wellington Management, Range Ventures, and Tao Capital Partners.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241205769962/en/

AMP will use the latest funding to accelerate the deployment of its AMP ONE™ systems. AMP ONE provides a full-scale facility solution to sort various material streams and capture more of the billions of dollars in value otherwise lost to landfills or incinerated annually. (Photo: Business Wire)

AMP will use the latest funding to accelerate the deployment of its AMP ONE™ systems, which are capable of cost-effectively sorting municipal solid waste (MSW), as demonstrated by the first-of-its-kind system AMP operates in Portsmouth, Virginia. Last month, AMP also entered into an agreement with Waste Connections, Inc. (TSX/NYSE: WCN) to equip and operate one of Waste Connections’ single-stream recycling facilities in Colorado. AMP ONE provides a full-scale facility solution to sort various material streams and capture more of the billions of dollars in value otherwise lost to landfills or incinerated annually.

“Recycling rates have stagnated in the United States, despite the positive benefits recycling offers local economies and the environment,” said Matanya Horowitz, founder of AMP. “This latest investment enables us to tackle larger projects and deliver real outcomes for waste companies and municipalities – by lowering sortation costs, capturing more material value, diverting organic waste, and extending landfill life – all while helping the industry optimize its strategic assets.”

AMP’s AI uses deep learning to continuously train itself by processing millions of material images into data. The software uses pattern recognition of colors, textures, shapes, sizes, and logos to identify recyclables and contaminants in real time, enabling new offtake chemistries and capabilities. AMP’s first products were a series of sorting robots deployed with minimal retrofit into existing recycling facilities. The company then pioneered a series of next-generation, transformative recycling facilities. With near-zero manual sorting, unprecedented reliability, and pervasive data, these facilities make the recovery of commodities safer and more cost-effective than ever and have grown to encompass MSW sorting, an offering out of reach to the industry prior to the advent of AMP’s technology.

Abe Yokell, co-founder and managing partner of Congruent Ventures, said, “AMP’s AI sortation systems enable consumers to recycle both with and without curbside separation and communities to benefit from the recovery of recycled commodities while reducing dependence on landfills. AMP is an example of the real-world impacts of AI; solutions like AMP’s will divert billions of tons of recyclable material from landfills while reducing emissions.”

Tim Stuart, chief executive officer for AMP, added, “AMP provides meaningfully lower-cost, higher-performance systems to recover commodities and increase landfill diversion, and we’re uniquely positioned to reshape the waste and recycling landscape at a critical time. We’re grateful to our longstanding and newest investors for their support in helping us chart a new path for sustainable materials management and resource efficiency.”

AMP recently augmented its leadership team with the appointment of Stuart, former chief operating officer for Republic Services Inc. (NYSE: RSG). Horowitz transitioned into the role of chief technology officer.

About AMP™

AMP is applying AI-powered sortation at scale to modernize the world's recycling infrastructure and maximize the value in waste. AMP gives waste and recycling leaders the power to harness AI to reduce labor costs, increase resource recovery, and deliver more reliable operations. The company’s AI platform has identified 150 billion items and guided the sortation of more than 2.5 million tons of recyclables. With three full-scale facilities and more than 400 AI systems deployed across North America, Asia, and Europe, AMP’s technology offers a transformational solution to waste sortation and changes the fundamental economics of recycling.

About Congruent Ventures

Congruent Ventures is a leading early-stage venture firm focused on partnering with entrepreneurs to build companies addressing climate and sustainability challenges across four themes: Mobility and Urbanization, the Energy Transition, Food and Agriculture, and Sustainable Production and Consumption. The firm has more than $1 billion in AUM across early-stage climate tech funds, making it one of the largest climate portfolios in early-stage venture. With 59 companies in the portfolio, Congruent is amongst the most active investors in the climate and sustainability ecosystem.

View source version on businesswire.com: https://www.businesswire.com/news/home/20241205769962/en/

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release

Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under

Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release

News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi

Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release

Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo

IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release

Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr

BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release

Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye